Despite potential hazards, elite endurance athletes appear to live longer than their contemporaries, a study in the European Heart Journal has found.
Researchers gathered mortality information on 786 French participants of the Tour de France from 1947 through 2012, comparing them to the general French population.
While 208 of the cyclists had died by 2012, they had a 41 percent reduction in mortality compared to people in the general population, gaining an estimated 6 years of life. Fewer cyclists suffered from cardiovasical disease, cancer, and respriotary or digestive diseases. However, they were more likely to die of traumatic causes.
"Although our results are reassuring to some extent, since no death has been observed since 1990, we have to remain careful since we cannot directly assess the potential harmfulness of doping through our analyses and results," the study author told Forbes.
The study co-author noted that athletes who compete in the Tour may have "superior genetic composition with lower disease susceptibility," making it hard to generalize the findings.
A similar study from the International Journal of Sports Medicine studying cyclists who rode the Tour between 1930 and 1964 also found that the professionals lived longer than people from the general population. The study authors noted that the cyclists smoke less, drink less alcohol, and have healthier diets than their peers.
Support Outside Online
Our mission to inspire readers to get outside has never been more critical. In recent years, Outside Online has reported on groundbreaking research linking time in nature to improved mental and physical health, and we’ve kept you informed about the unprecedented threats to America’s public lands. Our rigorous coverage helps spark important debates about wellness and travel and adventure, and it provides readers an accessible gateway to new outdoor passions. Time outside is essential—and we can help you make the most of it. Making a financial contribution to Outside Online only takes a few minutes and will ensure we can continue supplying the trailblazing, informative journalism that readers like you depend on. We hope you’ll support us. Thank you.